Bruce Rosengard

Bruce R. Rosengard is the Chief Medical Science and Technology Officer for Johnson & Johnson Medical Devices Companies. In this role, he is responsible for creating and delivering on a future oriented, strategic, and relevant medical innovation strategy. Dr. Rosengard and his team identify emerging surgical trends and novel technology platforms with the goal of bringing innovative device solutions in the surgical and interventional spaces into the Medical Devices portfolio.

A cardiothoracic surgeon and NIH-funded scientist, Dr. Rosengard, previously served as Vice President, New Business Ventures for The Medicines Company, where he played a pivotal role in several major acquisitions that have expanded the Medicines Company’s Surgical and Perioperative Care franchise. Before joining The Medicines Company, Dr. Rosengard was the Surgical Director of Cardiac Transplantation at Massachusetts General Hospital and on the faculty of Harvard Medical School.

Dr. Rosengard was graduated summa cum laude from Tufts University with a double major in Biology and Chemistry. He obtained his MD degree from John Hopkins, where he also completed his postgraduate training in general surgery, cardiothoracic surgery, and surgical critical care. Dr. Rosengard has authored more than 80 peer-reviewed publications, has given more than 40 invited talks at national or international meetings, and has served on the Boards of several professional societies.